Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$41.65 USD
-0.91 (-2.14%)
Updated May 6, 2024 04:00 PM ET
After-Market: $41.70 +0.05 (0.12%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Celldex Therapeutics, Inc. [CLDX]
Reports for Purchase
Showing records 161 - 180 ( 410 total )
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Acquisition of Kolltan Expands the Pipeline and Potential
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Announces Acquisition of Kolltan, Significant Dilution Ahead but New Assets Provide Additional Catalysts
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of September 26
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - The A to Z of HSCT: InvestorÂ’s guide to Hematopoietic Transplant Medicine
Provider: Roth Capital Partners, Inc.
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of August 22
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q, METRIC Enrollment Completion Delayed to 2017, Reiterate NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pushing Ahead on Multiple Fronts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q16 Results; Looking to Build Pipeline Momentum Again
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Emerging Therapies for Glioblastoma Multiforme: Updates from ASCO 2016
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.